Product Description
99% up Piroxicam Riacen 4-Hydroxy-2-methyl-3-(2-pyridylcarbamoyl)-2H-1,2-benzothiazine 1,1-dioxide 36322-90-4
AI Product Description
*The following content is generated by AI and is for reference only.
Piroxicam, chemically identified as 4-hydroxy-2-methyl-3-(2-pyridylcarbamoyl)-2H-1,2-benzothiazine 1,1-dioxide, is a potent non-steroidal anti-inflammatory drug (NSAID) widely utilized in clinical settings for the management of pain and inflammation. With the CAS Registry Number 36380-89-5, this compound belongs to the oxicam class of NSAIDs, characterized by its long half-life which allows for convenient once-daily dosing regimens. The molecular formula of Piroxicam is C15H13N3O4S, reflecting its complex heterocyclic structure comprising a benzothiazine ring system substituted with a pyridine carbamoyl group.
The primary therapeutic application of Piroxicam lies in the treatment of rheumatoid arthritis, osteoarthritis, and ankylosing spondylitis. It functions by inhibiting cyclooxygenase enzymes, specifically COX-1 and COX-2, thereby reducing the synthesis of prostaglandins that mediate pain, fever, and inflammatory responses. Its efficacy in alleviating joint stiffness and swelling has made it a standard option for chronic musculoskeletal disorders where sustained relief is required. Beyond orthopedic applications, it is occasionally prescribed for acute gouty arthritis and dysmenorrhea due to its strong analgesic properties.
Despite its clinical utility, Piroxicam carries a notable risk profile associated with gastrointestinal toxicity, including ulcers and bleeding, which necessitates careful patient monitoring. It also poses risks for cardiovascular events and renal impairment, particularly in elderly populations or those with pre-existing conditions. Consequently, medical guidelines often recommend using the lowest effective dose for the shortest duration possible. The product labeled as "Riacen" represents a specific pharmaceutical formulation of this active ingredient, ensuring bioavailability and therapeutic consistency. While newer NSAIDs with improved safety profiles exist, Piroxicam remains a valuable asset in pharmacotherapy for specific inflammatory conditions, provided that contraindications are strictly observed. Its distinct chemical structure and pharmacokinetic properties continue to support its relevance in modern medicine, balancing high efficacy against potential adverse effects through prudent clinical practice.
(All Rights Reserved)